MYC and breast cancer: We designed a sgRNA (single‐guide RNA) library for a genome‐wide disruption of MYC binding sites and conducted a high‐throughput screen in four MYC‐dependent cell lines: K562 (chronic myelogenous leukemia, CML), ST486 (Burkitt lymphoma, BL), HepG2 (hepatoblastoma), and MCF7 (breast cancer).